Overview

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Status:
Withdrawn

Trial end date:
2018-12-07

Target enrollment:

Participant gender:

Summary

This is a 12-week chronic-dosing study to assess the efficacy and safety of BGF MDI compared to BFF MDI in subjects with moderate to very severe COPD.

Phase:

Phase 3

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Budesonide
Formoterol Fumarate